IBD & Intestinal Disorders
News
Novel oral inhibitor may block intestinal damage in celiac disease
Randomized, phase 2 trial explored safety and efficacy of ZED1227, a transglutaminase inhibitor, after 6 weeks at three different doses.
News
Psychological difficulties persist among patients with IBD
“Simple screening tools may help with this, but then there need to be resources to support interventions,” said Dr. Kim L. Isaacs.
Conference Coverage
Vedolizumab looks safer than anti-TNF drugs in older adults with IBD
An analysis of a Medicare claims database finds vedolizumab is associated with efficacy similar to that of anti-TNF inhibitors, with fewer...
Article
AGA Clinical Practice Update: Diagnosis and management of immune checkpoint inhibitor enterocolitis and hepatitis
Some studies have suggested that colitis, with or without enteritis, affects up to 40% of patients depending on pathway targeted by the treatment...
Conference Coverage
NAFLD linked to worse outcomes in IBD
New nationwide analysis suggests involvement of nonmetabolic factors.
Conference Coverage
Racial, social inequities persist in IBD
Three in four patients are White, but there is growing appreciation of the diversity of the population and the need for equity in care.
Conference Coverage
COVID-19 risks linked to medications in IBD
Some drugs may lead to worse outcomes, though infection rates appear similar.
News
AGA publishes recommendations for managing IBD in elderly patients
Care of elderly IBD patients poses unique challenges with respect to diagnosis and therapeutic decision-making.
News
Histologic remission fails to be related to UC relapse
Relapse times in ulcerative colitis patients were similar regardless of histologic status in a retrospective study.
Conference Coverage
Rapid relief of opioid-induced constipation with MNTX
Subcutaneously administered, peripherally acting mu-opioid receptor antagonist, relieves opioid-induced constipation in both chronic, noncancer-...